22nd Sep 2020 18:01
(Alliance News) - GlaxoSmithKline PLC on Tuesday said it, alongside partner Sanofi SA, signed agreements with the government of Canada for the supply of up to 72 million doses of an adjuvanted Covid-19 vaccine, beginning in 2021.
Both drugmakers have vaccine manufacturing sites in Canada that are contributing to overall global Covid-19 vaccine development and their global industrial networks will play a pivotal role in the production of the Covid-19 vaccine doses for Canada, Glaxo noted.
Glaxo shares closed down 0.5% at 1,479.60 pence in London on Tuesday and Sanofi shares ended down 1.3% at EUR84.76 in Paris.
By Arvind Bhunjun; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline